首页> 外国专利> Use of laquinimod for Treatment of patients with Crohn's disease who failed therapy to anti tumour necrosis factor (anti TNFa), First Line

Use of laquinimod for Treatment of patients with Crohn's disease who failed therapy to anti tumour necrosis factor (anti TNFa), First Line

机译：拉喹莫德在治疗抗肿瘤坏死因子（抗TNFα）治疗失败的克罗恩病患者中的应用

页面导航

摘要
著录项
相似文献

摘要

Claim 45: a Pharmaceutical composition, which comprises a Unit dose lower than 0.5 mg laquinimod for Inducing and maintaining Clinical remission in a Human patient who suffers from Crohn's disease.

机译：45.一种药物组合物，其包含低于0.5mg拉喹莫德的单位剂量，用于诱导和维持患有克罗恩氏病的人类患者的临床缓解。

著录项

公开/公告号AR089862A1

专利类型
公开/公告日2014-09-24

原文格式PDF
申请/专利权人 TEVA PHARMACEUTICAL INDUSTRIES LTD.;
展开▼

申请/专利号AR2013P100296
发明设计人 NORA TARCIC;ASI HAVIV;ERAN BLAUGRUND;JOEL KAYE;
展开▼

申请日2013-02-01
分类号A61K31/4704;A61P1;A61P29;
国家 AR
入库时间 2022-08-21 15:58:48

相似文献

专利
外文文献
中文文献

1. Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two yea [J] . Joachim Sieper, Joachim Listing, Burkhard Muche, BMJ Open . 2017,第6期

2. Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two yea [J] . Joachim Sieper, Joachim Listing, Burkhard Muche, BMJ Open . 2017,第6期

3. An increase in serum tumour necrosis factor-alpha during anti-tumour necrosis factor-alpha therapy for Crohn's disease - A paradox or a predictive index? [J] . Eder Piotr, Korybalska Katarzyna, Lykowska-Szuber Liliana, Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2016,第10期

4. Anti-tumour necrosis factor therapy in clinical practice: what is advance and what is not? [C] . Falk Symposium . 2004

5. Yoga as an adjunctive therapy for Crohn's disease: A review of the effects of exercise and stress reduction on the quality of life and disease progression in Crohn's disease patients. [D] . Zuckerman, Julie. 2012

6. Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial [O] . Fabian Proft, Burkhard Muche, Joachim Listing, 2017

7. P573 Comparative effectiveness of second-line biological therapies for Ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment [O] . H K Hyun, J Yu, E A Kang, 2021

1. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? [J] . Ian C Lawrance . 世界胃肠病学杂志：英文版 . 2014,第5期

2. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy [J] . konstantinos papamichael ,adam s cheifetz . 世界胃肠病学杂志：英文版 . 2017,第34期

3. Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease [J] . Konstantinos Papamichael ,Severine Vermeire . 世界胃肠病学杂志：英文版 . 2015,第16期

4. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy [J] . Angela C Baird ,Dominic Mallon ,Graham Radford-Smith . 世界胃肠病学杂志：英文版 . 2016,第41期

5. Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease [J] . Christopher Ma ,Brennan Walters ,Richard N Fedorak . 世界胃肠病学杂志：英文版 . 2013,第21期

6. 重组人肿瘤坏死因子α衍生物3a(rh-TNFαD3a)治疗恶性肿瘤的临床研究 [C] . 夏阳 ,焦炳华 . 第15次全国干扰素及细胞因子学术会议 . 2006

7. 肿瘤坏死因子（TNF-α）及肿瘤坏死因子受体（TNFR-Ⅰ）在胆管癌中的表达 [A] . 贾友鹏 . 2003